Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979

Cancer Research

Volumn 56, Issue 18, 1996, Pages 4171-4179

  Dantzig, Anne H ^a   Shepard, Robert L ^a   Cao, Jin ^a   Law, Kevin L ^a   Ehlhardt, William J ^a   Baughman, Todd M ^a   Bumol, Thomas F ^a   Starling, James J ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; ETOPOSIDE; GLYCOPROTEIN P; PACLITAXEL; UNCLASSIFIED DRUG; VINBLASTINE; ZOSUQUIDAR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG PROTEIN BINDING; MULTIDRUG RESISTANCE; PRIORITY JOURNAL;

ANIMALS; BINDING SITES; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE; CELL MEMBRANE; CELL SURVIVAL; DIBENZOCYCLOHEPTENES; DRUG RESISTANCE, MULTIPLE; ETOPOSIDE; HUMANS; KINETICS; LEUKEMIA P388; LUNG NEOPLASMS; MICE; MICE, NUDE; P-GLYCOPROTEIN; PACLITAXEL; PROTEIN BINDING; QUINOLINES; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; VINBLASTINE;

EID: 0029809499     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Ford, J M., and Hait, W. N. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol. Rev., 42: 155-199, 1990
2. Naito, M., Oh-hara, T , Yamazaki, A., Kanki, T., and Tsuruo, T. Reversal of multidrug resistance by an immunosuppressive agent FK-506. Cancer Chemother. Pharmacol , 29 195-200, 1992.
3. Boesch, D., Muller, K., Pourtier-Manzanedo, A., and Loor, F Restoration of daunomycin retention in multidrug-resistant P388 cells by submicromolar concentrations of SDZ PSC 833, a nonimmunosuppressive cyclosporin derivative. Exp. Cell Res., 196: 26-32, 1991.
4. Boesch, D., Gaveriaux, C., Jachez, B., Pourtier-Manzanedo, A., Bollinger, P., and Loor, F. In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC833. Cancer Res., 51: 4226-4233, 1991
5. Pearce, H L., Safa, A. R., Bach, N. J., Winter, M A., Cirtain, M. C., and Beck, W. T. Essential features of the P-glycoprotem pharmacophore as defined by a series of reserpine analogs that modulate multidrag resistance. Proc. Natl. Acad. Sci. USA, 86: 5128-5132, 1989.
6. Sato, W., Fukuzawa, N., Suzuki, T., Yusa, K , and Tsuruo, T. Circumvention of multidrug resistance by a newly synthesized quinoline derivative, MS-073. Cancer Res , 51: 2420-2424, 1991.
7. Pierre, A., Dunn, T A., Kraus-Berthier, L., Leonce, S., Saint-Dizier, D., Regnier, G., Dhainaut, A., Berlion, M., Bizzari, J-P., and Atassi, G. In vitro and in vivo circumvention of multidrug resistance by Servier 9788, a novel triazinoaminopiperidine derivative. Invest. New Drugs, 10: 137-148, 1992
8. Hyafil, F., Vergely, C., Du Vignaud, P , and Grand-Perret, T. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res., 53: 4595-4602, 1993.
9. Slate, D. L , Bruno, N. A., Casey, S. M., Zutshi, N , Garvin, L. J., Wu, H , and Pfister, J R. RS-33295-198, a novel, potent modulator of P-glycoprotein-mediated multidrug resistance. Anticancer Res., 15: 1-4, 1995.
10. Pfister, J. R., Makra, F., Muehldorf, A. V , Wu. H., Nelson, J. T., Cheung, P., Bruno, N. A , Casey, S. M., Zutshi, N., and Slate, D. L Methanodibenzosuberylpiperazines as potent multidrug resistance reversal agents. Bioogr. Med. Chem. Lett., 5: 2473-2476, 1995.
11. Beck, W. T., Mueller, M. J., and Tanzer, L. R. Altered surface membrane glycoproteins in Vinca alkaloid-resistant human leukemic lymphoblast. Cancer Res., 39: 2070-2076, 1979.
12. Varki, N. M., Reisfeld, R. A , and Walker, R. E. Antigens associated with a human lung adenocarcinoma defined by monoclonal antibodies. Cancer Res., 44: 681-687, 1984.
13. Meyers, M., Rittmann-Grauer, L , O'Brien, J., and Safa, A. Characterization of monoclonal antibodies recognizing a 180 kDa P-glycoprotein differential expression of the 180 kDa and 170 kDa P-glycoproteins in multidrug-resistant human tumor cells Cancer Res., 49: 3209-3214, 1989.
14. Denizot, F., and Lang, R. Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability J. Immunol. Methods, 89: 271-277, 1989.
15. + gradient-stimulated uptake. J. Biol Chem., 252: 1990-1997, 1977.
16. Smith, P K., Krohn, R. I., Hermanson, G T., Mallia, A K., Garter, F. H., Provenzano, M D., Fujimoto, E K , Goeke, N M., Olson, B. J., and Klenk, D C. Measurement of protein using bicinchoninic acid. Anal. Biochem., 150: 76-85, 1985.
17. Laemmli, U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4 Nature (Lond.), 227: 680-685, 1970.
18. Cornwell. M. M., Gottesman, M M , and Pastan, I. H. Increased vinblastine binding to membrane vesicles from multidrug-resistant KB cells. J Biol. Chem., 261: 7921-7928, 1986.
19. 2+-dependent binding of vincristine to the plasma membrane of multidrug-resistant K562 cells. J. Biol. Chem , 263: 11887-11891, 1988
20. Fiske, C. H., and Subbarow, Y The colorimetric determination of phosphorous. J Biol. Chem., 66: 375-400, 1925.
21. Speeg, K. V., and Maldonado, A L. Effect of the nonimmunosuppressive cyclosporin analog SDZ PSC-833 on colchicine and doxorubicin biliary secretion by the rat in vivo. Cancer Chemother. Pharmacol., 34: 133-136, 1994.
22. Harvey, V. J., Joel, S. P., Johnston, A., and Slevin, M. L. High performance liquid chromatography of etoposide in plasma and urine. J. Chromatog., 339: 419-423, 1985
23. Doige, C. A., Yu, X., and Sharom, F. J. ATPase activity of partially purified P-glycoprotem from multidrug-resistant Chinese hamster ovary cells Biochim. Biophys. Acta, 1109: 149-160, 1992.
24. r 170,000 to 180,000 membrane glycoprotein (P-glycoprotein) associated with multidrug resistance in K562/ADM cells Cancer Res , 48: 4926-4932, 1988.
25. Sharom, F. J., Yu, S., and Doige, C. A. Functional reconstitution of drug transport and ATPase activity in proteoliposomes containing partially purified P-glycoprotein. J. Biol. Chem., 268: 24197-24202, 1993.
26. Lum, B. L., and Gosland, M. P MDR expression in normal tissues. Pharmacologic implications for the clinical use of P-glycoprotem inhibitors. Hematol. Oncol. Clin. N. Am , 9: 319-336, 1995.
27. Bartleu, N L., Lum, B L , Fisher, G. Z., Brophy, N. A., Ehsan, M. N., Halsey, J., and Sikic, B. I. Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance J. Clin Oncol , 12: 835-842, 1994.
28. Colombo, T., Zucchetti, M., and D'incalci, M Cyclosporin A markedly changes the distribution of doxorubicin in mice and rats. J. Pharmacol. Exp Ther., 269: 22-27, 1994
29. Lum, B. L , Kaubisch, S., Yahanda, A. M., Adler, K. M., Jew, L , Ehsan, M. N., Brophy, N A., Halsey, J., Gosland, M. P., and Sikic, B. I. Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. J Clin Oncol., 10: 1635-1642, 1992.
30. Lum, B. L , Fisher, G. A., Brophy, N A , Yahanda, A. M., Adler, K. M., Kaubisch, S., Halsey, J , and Sikic, B. I. Clinical trials of modulation of multidrug resistance. Pharmacokinetic and pharmacodynamic considerations. Cancer (Phila.), 72: 3502-3514, 1993
31. Volm, M., Mauern, J., and Samsel, B. Overexpression of P-glycoprotem and glutathione S-transferase-π in resistant non-small cell lung carcinoma of smokers Br. J. Cancer, 64: 700-704, 1991.
32. Johnson, D. H., and Einhorn, L H. Paclitaxel plus carboplatin an effective combination chemotherapy for advanced non-small cell lung cancer or just another Elvis sighting? J. Clin. Oncol., 13: 1840-1842, 1995.
33. Lum, B. L., Fisher, M. D., Hausdorff, J., Gottwald, M., Collins, H., Brophy, N. A., Ehsan, M. N., Halsey, J , and Sikic, B. I. The effect of oral SDZ PSC833, a cyclosporin D analog, on the pharmacokinetic behavior of etoposide (E) during a phase 1 trial to modulate multidrug resistance. Anticancer Drugs, 5: 44, 1994.
34. Gibaldi, M. Drug interactions: part II. 26: 829-834, 1992.
35. Spatzenegger, M , and Jaeger, W. Clinical importance of hepatic cytochrome P450 in drug metabolism Drug Metab. Rev., 27: 397-412, 1995
36. Wacher, V. J., Wu, C. Y., and Benet, L. Z. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy Mol. Carcinog., 13: 129-134, 1995.
37. Bohme, M., Buchler, M , Müller, M., and Keppler, D. Differential inhibition by cyclosporins of primary-active ATP-dependent transporters in the hepatocyte canalicular membrane. FEBS Lett , 333: 193-196, 1993.
38. Buchler, M., Bohme, M , Ortlepp, H , and Keppler, D. Functional reconstitution of ATP-dependent transporters from the solubilized hepatocyte canalicular membrane. Eur. J. Biochem. 224: 345-352, 1994.
39. Safa, A. R. Photoaffinity labeling of P-glycoprotein in multidrug-resistant cells. Cancer Invest., 10: 295-305, 1992.